Community Acquired Infection

ORIGINAL ARTICLE
Year
: 2015  |  Volume : 2  |  Issue : 3  |  Page : 93--96

Efficacy and safety of moxifloxacin injection in treatment of acute exacerbation of chronic bronchitis


Tiantuo Zhang1, Ping Chen2, Chengshui Chen3, Jiulong Kuang4, Changzheng Wang5, Xixin Yan6, Xiaohong Yang7, Yuxia Shao8, Xiaochun Yang9 
1 Department of Respiratory, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
2 Department of Respiratory, The Second Xiangya Hospital of Central South University, Changsha, China
3 Department of Respiratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
4 Department of Respiratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China
5 Department of Respiratory, Xinqiao Hospital, The Third Military Medical University, Chongqing, China
6 Department of Respiratory, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, China
7 Department of Respiratory, People's Hospital of Xinjiang Uygur Autonomous Regin, Urumqi, China
8 Department of Respiratory, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
9 Department of Respiratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China

Correspondence Address:
Tiantuo Zhang
Department of Respiratory, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou
China

Objective: To evaluate the clinical efficacy and safety of moxifloxacin injection in the treatment of acute exacerbation of chronic bronchitis (AECB) in daily clinical practice. Patients and Methods: From May 2009 to March 2011, a total of 1026 cases with AECB were collected from 43 hospitals in eight cities. All the patients were treated with moxifloxacin (400 mg qd) intravenously. Whether to use oral or sequential therapy was decided by the physicians according to the clinical efficacies. Patient conditions such as combined uses of drugs, efficacies and adverse events were recorded and analyzed. Results: The cure rate of infection was 83.03%, and the total effective rate of moxifloxacin injection was 93.80%. The efficacies were statistically different among subgroups with different ages, complications, forced expiratory volume in 1 s (FEV 1 %), and combined uses of drugs, respectively. Multivariable logistic regression analysis showed that the advanced age (≥65 years) and severe obstructive pulmonary disease (FEV 1 <50%) were significantly correlated with the clinical efficacies. A total of 15 cases of adverse events were recorded, and the incidence rate was 1.23%. Conclusion: Moxifloxacin injection can effectively control the infection of AECB patients with fewer adverse events.


How to cite this article:
Zhang T, Chen P, Chen C, Kuang J, Wang C, Yan X, Yang X, Shao Y, Yang X. Efficacy and safety of moxifloxacin injection in treatment of acute exacerbation of chronic bronchitis.Community Acquir Infect 2015;2:93-96


How to cite this URL:
Zhang T, Chen P, Chen C, Kuang J, Wang C, Yan X, Yang X, Shao Y, Yang X. Efficacy and safety of moxifloxacin injection in treatment of acute exacerbation of chronic bronchitis. Community Acquir Infect [serial online] 2015 [cited 2021 Nov 28 ];2:93-96
Available from: http://www.caijournal.com/article.asp?issn=2225-6482;year=2015;volume=2;issue=3;spage=93;epage=96;aulast=Zhang;type=0